Shaily Engineering Plastics Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, during a Board meeting held on August 8, 2026. The Board also fixed Friday, September 11, 2026, as the record date for determining members entitled to receive the final dividend for FY 2025-26. Additionally, the company reappointed Amit Mahendra Sanghvi as Managing Director, effective from October 1, 2026, to September 30, 2031, subject to shareholder approval at the forthcoming 46th Annual General Meeting.

The Board Meeting commenced at 2:15 p.m. and concluded at 5:20 p.m. on August 8, 2026. The proceedings were conducted in compliance with Regulation 30(6) of the SEBI Listing Regulations, 2015. Details regarding the reappointment of the Managing Director were disclosed in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFDDPO2/I/3762/2026 dated January 30, 2026.

Key Board Decisions

The Board transacted several key items during the session:

• Financial Results: Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026, were considered and approved.
• Dividend Record Date: Pursuant to Regulation 42 of the SEBI Listing Regulations, the Company fixed Friday, September 11, 2026, as the Record Date for the final dividend for FY 2025-26.
• Management Reappointment: Reappointment of Mr. Amit Mahendra Sanghvi as Managing Director was approved, effective from October 1, 2026, to September 30, 2031.
• Compliance: Approval of the revised Code of Conduct for Prevention of Insider Trading in the Securities of the Company.

Management Profile

Amit Mahendra Sanghvi (DIN: 00022444) brings extensive experience in supply chain and manufacturing. An Electrical Engineer from the University of Ottawa with an M.Sc. in Supply Chain and Manufacturing from Pennsylvania State University, he began his career with Arete Inc. (USA) and later worked with Pepsi Bottling Group and Coca Cola Bottling Indonesia. At Shaily Engineering Plastics, he started as General Manager – Projects before being elevated to Whole-Time Director and subsequently Managing Director in May 2015. He is the son of Executive Chairman Mahendra Sanghvi and Whole-Time Director Tilottama Sanghvi.

Corporate Governance Updates

The reappointment of Amit Mahendra Sanghvi requires shareholder approval at the upcoming Annual General Meeting. The company has ensured transparency by providing details as per Annexure A in the regulatory filing. The revised Code of Conduct for Prevention of Insider Trading reflects the company's ongoing commitment to regulatory compliance and market integrity.

Shaily Engineering Plastics delivered a robust financial performance in Q1FY27, with standalone net profit after tax (PAT) surging 46% year-on-year to ₹52.47 crore. The strong bottom-line growth was underpinned by an 85% surge in healthcare segment revenue to ₹142.4 crore, which offset a 24% decline in consumer demand. Consolidated EBITDA margins expanded by 120 basis points (bps) to 29.7%, reflecting improved operational efficiency and higher machine utilization across its Gujarat facilities.

The Board of Directors approved the unaudited financial results on August 08, 2026, in compliance with Regulation 33 of the SEBI Listing Regulations, 2015. Statutory auditors B S R and Co. issued an unmodified limited review report. The company also released its Q1 & FY27 Investor Presentation, highlighting new business confirmations in semaglutide pens supply for Canada and Brazil, as well as projects from FMCG and automotive clients.

Financial Performance Highlights

Consolidated revenue from operations rose 14% YoY to ₹280.7 crore. While standalone PAT jumped 46%, consolidated PAT grew 17% to ₹48.0 crore, indicating that subsidiary performance diluted the overall growth rate slightly. Cash PAT, defined as PAT plus depreciation, increased 18% to ₹62.1 crore.

Segment-Wise Revenue Breakdown

The healthcare segment emerged as the primary growth driver, with revenue rising 85% to ₹142.4 crore from ₹77.2 crore in Q1FY26. This growth was fueled by customer approvals for semaglutide pen supplies and two new IP-led platform projects. Conversely, the consumer segment faced weaker market demand in Europe and the USA, leading to a 24% revenue drop to ₹115.5 crore. The industrial segment grew 25% to ₹22.7 crore, supported by new projects in appliances, consumer electronics, and automotive components.

What the Numbers Show

The divergence between standalone and consolidated profitability highlights the impact of subsidiary operations. While the parent entity achieved a 46% PAT surge, consolidated PAT grew only 17%. This suggests that subsidiaries, including Shaily Innovations Ltd and Shaily Innovations FZCO, contributed less proportionally to bottom-line growth. Notably, one subsidiary reported a net loss of ₹1.97 crore, which was deemed immaterial but diluted aggregate profit expansion. However, the group’s overall health remains strong, with Return on Capital Employed (RoCE) improving by 320 bps to 39.0% and Total Debt/Equity ratio decreasing from 0.3 to 0.2.